John Sununu - Boston Scientific Independent Director
| BSX Stock | USD 90.75 0.54 0.60% |
Director
Sen. John E. Sununu Jr. is Independent Director of the Company. Senator Sununu served as a U.S. Senator from New Hampshire from 2003 to 2009. He was a member of the Committees on Banking, Commerce, Finance and Foreign Relations, and he was appointed the Congressional Representative to the United Nations General Assembly. Before his election to the Senate, Senator Sununu served three terms as a Member of the U.S. House of Representatives from New Hampshire 1st District from 1996 to 2002. He was Vice Chairman of the Budget Committee and a member of the Appropriations Committee. During his twelve years in Congress, he drafted and helped pass several important pieces of legislation, including the Internet Tax Freedom Act, the Survivors Benefit Act and the New England Wilderness Act. Prior to serving in Congress, Senator Sununu served as Chief Financial Officer for Teletrol Systems, a manufacturer of building control systems. Senator Sununu formerly served as a director of Time Warner Cable Inc. since 2009.
| Age | 56 |
| Tenure | 15 years |
| Address | 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234 |
| Phone | 508 683 4000 |
| Web | https://www.bostonscientific.com |
Boston Scientific Management Efficiency
The company has Return on Asset of 0.049 % which means that on every $100 spent on assets, it made $0.049 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0892 %, implying that it generated $0.0892 on every 100 dollars invested. Boston Scientific's management efficiency ratios could be used to measure how well Boston Scientific manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Boston Scientific's Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.14 in 2024, whereas Return On Equity is likely to drop 0.06 in 2024. At this time, Boston Scientific's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 30.1 B in 2024, whereas Other Current Assets are likely to drop slightly above 544.2 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Maria Hilado | Zimmer Biomet Holdings | 56 | |
| Duncan Nichol | STERIS plc | 76 | |
| Robert Alpern | Abbott Laboratories | 70 | |
| Nancy McKinstry | Abbott Laboratories | 62 | |
| Sally Blount | Abbott Laboratories | 59 | |
| Michael Michelson | Zimmer Biomet Holdings | 69 | |
| Samuel Scott | Abbott Laboratories | 75 | |
| Sherilyn McCoy | Stryker | 62 | |
| Paul LaViolette | Edwards Lifesciences Corp | 63 | |
| Christopher Holland | STERIS plc | 54 | |
| Robin Freestone | Smith Nephew SNATS | 61 | |
| Michael Farrell | Zimmer Biomet Holdings | 48 | |
| James Lenehan | Medtronic PLC | 71 | |
| Andrew Silvernail | Stryker | 50 | |
| Kieran Gallahue | Edwards Lifesciences Corp | 57 | |
| John Stratton | Abbott Laboratories | 60 | |
| Patricia Gonzalez | Abbott Laboratories | 49 | |
| Loyal Wilson | STERIS plc | 70 | |
| Allan Golston | Stryker | 54 | |
| Michael Leavitt | Medtronic PLC | 69 | |
| Katarzyna MazurHofsaess | Smith Nephew SNATS | 57 | |
Management Performance
| Return On Equity | 0.0892 | ||||
| Return On Asset | 0.049 |
Boston Scientific Corp Leadership Team
Elected by the shareholders, the Boston Scientific's board of directors comprises two types of representatives: Boston Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boston. The board's role is to monitor Boston Scientific's management team and ensure that shareholders' interests are well served. Boston Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boston Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Ludwig, Lead Independent Director | ||
| Donna James, Independent Director | ||
| Stephen MacMillan, Independent Director | ||
| Michael Mahoney, Chairman of the Board, President, Chief Executive Officer | ||
| Emily Woodworth, Global VP | ||
| Kevin Ballinger, Executive Vice President and Global President - Interventional Cardiology | ||
| Desiree RallsMorrison, Senior Vice President General Counsel, Corporate Secretary | ||
| Maulik Nanavaty, Senior Vice President and President - Neuromodulation | ||
| Ian Meredith, Executive Vice President Global Chief Medical Officer | ||
| David Pierce, Executive Vice President and President, MedSurg and President - Endoscopy | ||
| Ellen Zane, Independent Director | ||
| Joseph Fitzgerald, Executive Vice President, President, Interventional Cardiology | ||
| Eric Thepaut, Executive Vice President and President - Europe, Middle East and Africa | ||
| Daniel Brennan, CFO, Principal Accounting Officer and Executive VP | ||
| Nelda Connors, Independent Director | ||
| Wendy Carruthers, Executive Vice President - Human Resources | ||
| Jodi Eddy, Senior Vice President and Chief Information and Digital Officer | ||
| Catherine Jennings, VP Interventions | ||
| John Sorenson, Senior Vice President - Manufacturing and Supply Chain | ||
| Arthur Butcher, Executive Vice President and President, Asia Pacific | ||
| Daniel CPA, Executive CFO | ||
| Edward Mackey, Executive Vice President - Global Operations | ||
| Scott Olson, Senior Vice President, President - Cardiac Rhythm Management and Diagnostics | ||
| Vance Brown, Senior Vice President General Counsel, Corporate Secretary | ||
| Charles Dockendorff, Independent Director | ||
| Mary Moynihan, Senior Officer | ||
| John Sununu, Independent Director | ||
| Jeffrey Mirviss, Executive Vice President and President - Peripheral Interventions | ||
| Yoshiaki Fujimori, Independent Director | ||
| David Wichmann, Independent Director | ||
| David Roux, Independent Director | ||
| Susan Lisa, VP, Investor Relations | ||
| Jonathan Monson, Chief Accounting Officer, Vice President Global Controller | ||
| Jeffrey MBA, Executive Interventions | ||
| Meghan Scanlon, Senior Vice President and President - Urology and Pelvic Health |
Boston Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boston Scientific a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0892 | ||||
| Return On Asset | 0.049 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 142.51 B | ||||
| Shares Outstanding | 1.47 B | ||||
| Shares Owned By Insiders | 0.18 % | ||||
| Shares Owned By Institutions | 92.47 % | ||||
| Number Of Shares Shorted | 11.02 M | ||||
| Price To Earning | 107.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Boston Stock Analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.